Polynovo Limited · ASX:PNV
Polynovo — Conference Presentation (October 2019)
30 slides from Polynovo's conference presentation, Oct 24, 2019
Slide 1: PolyNovo Limited New York Investor Presentation
For personal use only PolyNovo Limited New York Investor Presentation 23 & 24 October 2019 22 August 2019 ASX: PNV
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or u
Slide 3: NovoSorb polymer: a unique platform technology
NovoSorb® polymer A unique platform technology For personal use only NovoSorb® • Base polymer developed by the CSIRO (Australian Government research) and spun out as PolyNovo • Unique polymer technology, Carbamate, that is programmable for re-absorbsion rate and product attributes. • Excellent bioco
Slide 4: Addressable Markets - Near term
Addressable Markets - Near term For personal use only NovoSorb BTM is currently on sale • Unique biodegradable purely synthetic • Market expansion for the use of dermal scaffolds Pipeline development – a platform technology • Hernia devices preparing for manufacturing scale up with equipment deliver
Slide 5: NovoSorb BTM fully resorbed
NovoSorb BTM fully resorbed For personal use only Flexible, smooth normal tissue! 5
Slide 6: When BTM is placed in a wound
When BTM is placed in a wound For personal use only NovoSorb BTM applied to debrided wound bed 1 The wound is ‘physiologically closed’, limiting contraction and risk of infection. NovoSorb BTM fully integrated 2 Full thickness tissue deposited within the foam. Once integrated, the seal is ready for
Slide 7: How does NovoSorb BTM work?
How does NovoSorb BTM work ? For personal use only The BTM foam breaks up a large wound (marcrowound) into a series of small, interconnected microwounds. The body easily heals microwounds, promoting organized regenerative healing. Normal Healing: The body’s natural Healing with BTM: The NovoSorb foa
Slide 8: Foam structure
Foam structure For personal use only • Yellow segments demonstrate what you see in the histopathology- edges of foam structure • Red circle highlights communicating pores • Yellow circle highlights the cellular chambers of the foam • Blue circle demonstrates the artifact of cutting the foam chambers
Slide 9: Blanching & Delamination
Blanching & Delamination For personal use only 9 9
Slide 10: Allows for Staged Grafting
Allows for Staged Grafting For personal use only Note the maturity of this graft 7 days post- application. The mesh spaces are closed. A truly outstanding result. Pt 5 Day 31 post-NovoSorb BTM Pt 5 Day 38 post- NovoSorb BTM Page 10 10 10
Slide 11: Necrotising Fasciitis
Necrotising Fasciitis Anterior Cervical and Upper Thoracic For personal use only Three months 12 post grafting 12
Slide 12: Necrotising Fasciitis Applications
Necrotising Fasciitis Applications For personal use only Debrided Wound 4 days after skin graft Day 77: full range of movement! 13
Slide 13: Necrotising Fasciitis Application
Necrotising Fasciitis Application For personal use only NovoSorb BTM applied Ready to graft Day 62 post-graft 2 weeks post-graft Fully debrided flank - ribs exposed 14
Slide 14: NovoSorb BTM over tendon
NovoSorb BTM over tendon For personal use only Degloving injury with tendons missing the paratenon. NovoSorb BTM was left on for 9 weeks before grafting. Day 316 15
Slide 15: Improving peoples lives
Improving peoples lives For personal use only After the train crushed his foot, Malcom was told a below the knee amputation was the only solution. That outcome wasn’t acceptable to Malcom or his surgeon. BTM helped to re-cover his exposed structures so his body could heal. Today he stands tall despi
Slide 16: Improving patient's lives
Improving patient’s lives For personal use only Noah doesn’t remember the sound of the explosion. But he does remember waking up on fire as the flames burned through his gasoline-soaked skin. Noah received 3rd degree burns to over half of his body potentially altering the trajectory of this young ma
Slide 17: NovoSorb BTM current market entries
NovoSorb BTM current market entries For personal use only Europe Middle East ⚫ CE mark expected anytime now ⚫ Israel Sept 2018 ⚫ UK direct entry 1 sales person will add 2 ⚫ Saudi Arabia Sept 2018 ⚫ Germany distributor PMI ready to India and SE Asia launch ⚫ Other EU markets consider direct ⚫ Myovate
Slide 18: Highlights of FY19
For personal use only Highlights of FY19 20
Slide 19: Driving expansion
Driving expansion For personal use only • Purchased adjacent building for hernia and breast device manufacturing • Purchase / commissioning of new machinery for hernia and breast device manufacturing • Direct sales person in UK sales pending CE Mark, will add another 2. Evaluation sites ready • New
Slide 20: Depth of Talent
Depth of Talent For personal use only • Increased headcount to 36 (June 18) 47 (June 19) 60 (August) • Appointment of Jan Gielen CFO • Appointment of Ashok Srinivasan COO • Appointment of Monica Benyk as HR manager • Appointed 1st sales person in UK/Ireland in anticipation of CE Mark approval (immin
Slide 21: Production Capacity
Production Capacity For personal use only • Have run 2 shifts to build inventory • Currently hold 6 months forward inventories on a rolling forecast basis • Capacity increase through: • Centralised larger polyol reactor in combined Hernia/BTM facility (unit 1) • Centralised Foam production in dedica
Slide 22: Clinical Trial update
Clinical Trial update For personal use only • CE Burn trial is complete with final publication of results due by end of Feb/March 2020 • BARDA funded Feasibility trial results will be published ~ March 2020 sites were • Wake Forest Baptist Health, Winston-Salem, • University of Tennessee Medical Cen
Slide 23: Strategy for FY20
Strategy for FY20 For personal use only • Significant expansion of sales of BTM in the US, Australia and New Zealand. • Increased sales reach/ capacity • Exciting new product pipeline in breast and hernia. • Increasing manufacturing capacity commission hernia production • File Hernia US FDA 510(K) e
Slide 24: Top shareholders
Top 20 shareholders For personal use only Top 20 Shareholders October 2019 Units % of Units 1. HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED 74,386,881 11.25 2. J P MORGAN NOMINEES AUSTRALIA PTY LIMITED 45,687,562 6.91 3. CITICORP NOMINEES PTY LIMITED 28,456,407 4.30 4. MOGGS CREEK PTY LTD <MOGGS CREEK
Slide 25: It takes a team
For personal use only It takes a team 27
Slide 26: The Board
The Board PNV For personal use only Mr David Williams (B.Ec (Hons), M.Ec, FAICD) Non-executive Chairman Mr Williams was appointed as a Nonexecutive Director on 28 February 2014 and Chairman on 13 March 2014. Mr Williams is an experienced Director and investment banker with a proven track record in b
Slide 27: The Board (2)
The Board (2) For personal use only Mr Bruce Rathie (B.Comm, LLB, MBA, FAIM, FAICD, FGIA) Non-executive Director Mr Rathie is an experienced Company Director with a finance and legal background. He practised as a partner in a large legal firm and acted as Senior Corporate Counsel to Bell Resources L
Slide 28: Management
Management For personal use only Mr Paul Brennan (MBA, BSc (Nursing) RN RM) Chief Executive Officer Mr Brennan was appointed Chief Executive Officer (CEO) of PolyNovo Ltd on 13 February 2015. Mr Brennan has extensive knowledge, exposure and understanding of the health system through his clinical bac
Slide 29: Management (2)
Management (2) For personal use only Dr. Tim Moore Principle Scientist completed a Bachelor of Applied Science (Chemistry) degree at Swinburne University of Technology, followed by an honours degree and PhD degree. Dr. Moore’s PhD dissertation was in the field of biodegradable polyurethanes; the tit
Slide 30: John Weeks 1st patient treated with NovoSorb BTM
John Weeks 1st patient For personal use only treated with NovoSorb BTM 32